Drug Profile
Meclocycline
Alternative Names: SNX-1012Latest Information Update: 20 Jul 2015
Price :
$50
*
At a glance
- Originator Mucosal Therapeutics LLC
- Developer Coserics
- Class Antibacterials; Tetracyclines
- Mechanism of Action Interleukin 6 inhibitors; NF-kappa B inhibitors; Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Stomatitis
Most Recent Events
- 01 Aug 2007 SNX 1012 is still in phase II trials for Stomatitis in USA
- 11 Nov 2005 Phase-II clinical trials in Stomatitis in USA (PO)
- 22 Jun 2005 Phase I trials have been completed in Stomatitis